Also known as: beta blockers, beta-blockers, Beta-blockers
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Mavacamten significantly reduces heart obstruction in adolescents with hypertrophic cardiomyopathy, with patients experiencing a 48.5 mm Hg drop in blockage compared to minimal change in placebo groups. The drug also lowered blood markers indicating heart damage and showed promise in slowing disease progression. Separate real-world data confirms mavacamten's effectiveness as monotherapy across diverse patient populations.
New research shows home-based exercise reduces cognitive impairment during chemotherapy, while cardio-oncology programs monitor and minimize heart complications from cancer treatments that pose cardiovascular risks to survivors.
Praxis Precision Medicines has submitted new drug applications for ulixacaltamide in essential tremor and relutrigine in rare epilepsies, both granted Breakthrough Therapy Designation. The company reported $926 million in cash as of December 31, 2025.
